Healthcare Industry News: intraocular lens
News Release - July 17, 2008
Carl Zeiss Meditec Reaches 1,000 Cirrus(TM) HD-OCT Placements
Most Advanced Optical Coherence Tomography System Achieves Record Adoption in Less Than One YearDUBLIN, Calif.--(HSMN NewsFeed)--Carl Zeiss Meditec, a leader in ophthalmic devices and surgical systems, today announced that it has installed the 1,000th Cirrus™ HD-OCT system at Pima Eye Institute in Tucson, Arizona. First introduced in November 2007, Cirrus HD-OCT has achieved broad acceptance in the ophthalmic industry and is rapidly becoming the standard of care for identifying retinal and glaucoma disease characteristics and for monitoring disease progression.
“We researched all the leading optical coherence tomography platforms on the market today and chose Cirrus for several key reasons,” said Ajay Sanan, MD, an ophthalmic surgeon at Pima Eye Institute. “Based on our first-hand experience, Zeiss consistently delivers high quality technology and we were confident that Cirrus would keep with this longstanding tradition. The glaucoma analysis capabilities surpass those of any other platform. For our cataract and retina patients, the individual HD layer maps help us to uncover retinal pathologies and explain why a patient does not see as well as expected. Even with these expected benefits, we have been surprised by the utility and efficiency of this system and use it for a far greater percentage of our patients than we had originally predicted.” Pima Eye Institute provides specialty eye care to the Southern Arizona community.
Integration of the 1,000th Cirrus platform was achieved seamlessly at Pima Eye Institute, according to ophthalmology technician, Christina Schiermeyer. ”The Cirrus is straightforward and easy to use. After a quick training session, we have been able to smoothly operate the machine to capture excellent images.”
The Cirrus HD-OCT is the first spectral domain technology instrument to offer high definition 3D maps of individual retinal layers to reveal pathology hidden within the retinal tissue. The Cirrus also automates patient and image alignment to ensure precision and measurement reproducibility critical to glaucoma patient assessment. These advanced imaging and analysis capabilities enable physicians to more confidently diagnose patients with retinal disease and glaucoma and monitor treatment results.
“With more than a decade of experience, Zeiss has the longest track record of research, engineering and product development in the field of OCT,” said Jim Taylor, president and chief executive officer of Carl Zeiss Meditec. “The Cirrus platform is in high demand because of the significant clinical and practice management benefits that it has demonstrated in the field. One key attribute is that it makes detailed information more tangible and accessible, providing workflow and operational efficiencies for clinicians and technicians.”
The Cirrus HD-OCT is the latest addition to the Zeiss family of OCT imaging devices, a technology suite that is designed to meet the evolving needs of the ophthalmic practice, the aging patient population and the healthcare system. Zeiss continues to invest in each of its OCT products, which in addition to the Cirrus HD-OCT, include the Stratus™ OCT and the Visante™ OCT.
About Carl Zeiss Meditec
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world’s leading medical technology companies. This market position is based on over 160 years of experience in optical innovation.
The company has two primary areas of activity: In the field of ophthalmology Carl Zeiss Meditec offers integrated solutions for treating the four main eye ailments: vision defects (refraction), cataract, glaucoma and retinal disorders. The company’s system solutions are employed in all phases of the disease management, from diagnosis to treatment and aftercare. Carl Zeiss Meditec has always applied its technological expertise to product innovations. These innovations range from basic systems such as slit lamps and fundus cameras to standard setting diagnostic systems such as the Humphrey® Field Analyzer, the Stratus OCT™ and the IOLMaster®, through to the surgical microscopes and innovative treatment systems in refractive laser surgery. The product portfolio in ophthalmic surgery is rounded off by intraocular lenses and consumables.
In the field of neuro and ENT surgery, Carl Zeiss Meditec is the world’s leading provider of surgical microscopes and microsurgical visualization solutions for a very broad range of applications, such as tumor and vascular surgery in the head region and/or spinal surgery. The most recent example of the innovative performance in the area of microsurgery is the OPMI Pentero® visualization system, which allows efficient and ergonomic patient treatment. Carl Zeiss Meditec will systematically expand its product range in this area and become a solution provider in neuro and ENT surgery as well.
Carl Zeiss Meditec’s medical technology portfolio is rounded off by visualization systems for doctors in private practice and promising future technologies such as intraoperative radiation therapy, which allows the targeted treatment of breast cancer and brain cancer directly during surgery.
Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Surgical GmbH, Carl Zeiss Meditec Vertriebsgesellschaft mbH, *Acri.Tec AG and Carl Zeiss Medical Software GmbH), the USA (Carl Zeiss Meditec, Inc., Dublin), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec Iberia S.A., Madrid) and France (Carl Zeiss Meditec S.A.S., La Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq).
Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss, one of the world’s leading international groups engaged in the optical and opto-electronics industry.
Source: Carl Zeiss Meditec
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
